Explanipedia

Structural basis for hepatitis E virus neutralization by potent human antibodies Open

Luis M. Molinos‐Albert, Eduard Baquero, Cyril Planchais, Virginie Doceul, Hicham El Costa , et al. · 2025

Antibodies targeting the hepatitis E virus (HEV) surface capsid protein (CA) are essential for infection control and resolution, yet their molecular and functional attributes remain largely elusive. We characterized 144 human HEV-CA–specif…

[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study Open

Jean‐Charles Nault, Marouane Boubaya, Myriam Wartski, Anthony Dohan, Stanislas Pol , et al. · 2025

Carcinome Hépatocellulaire (CHC) Open

Stanislas Pol · 2024

Hepatocellular carcinoma (HCC) Primary liver cancers are tumors that develop from different liver cells. Hepatocellular carcinoma (HCC), which develops from hepatocytes, accounts for approximately 75-85% of primary liver cancers. HCC is th…

ACBP/DBI neutralization for the experimental treatment of fatty liver disease Open

Omar Motiño, Flavia Lambertucci, Adrien Joseph, Sylvère Durand, Gerasimos Anagnostopoulos , et al. · 2024

Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study Open

Stanislas Pol, Alexander Thompson, Michelle A. Collins, Elisa Venier, Laurent Cotte , et al. · 2024

Background and Aims: No direct-acting antiviral is currently approved for acute HCV infection, delaying treatment. We investigated the effectiveness and safety of 8-week glecaprevir/pibrentasvir (G/P) in patients with acute HCV infection. …

Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort Open

Arnaud Nze Ossima, Angélique Brzustowski, Valérie Paradis, Bernard E. Van Beers, Catherine Postic , et al. · 2024

Histological characterization of liver involvement in systemic mastocytosis Open

Julien Rossignol, Danielle Canioni, Achille Aouba, C. Bulaï Livideanu, Stéphane Barète , et al. · 2024

Background and Aims Systemic mastocytosis (SM) is characterized by the accumulation of atypical mast cells (MCs) in organs. Liver histology of SM has been marginally described and accurate histological classification is critical, given the…

Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort Open

Victor de Lédinghen, Claire Fougerou‐Leurent, Estelle Le Pabic, Stanislas Pol, Dulce Alfaiate , et al. · 2024

Bulevirtide is the only EMA-approved drug for HDV treatment, and we showed that it can be used in adults living with HIV, with an overall good tolerability. Bulevirtide induces a virological response in more than 50% of patients, suggestin…

Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide Open

Selma El Messaoudi, Ségolène Brichler, Claire Fougerou‐Leurent, Emmanuel Gordien, Athénaïs Gerber , et al. · 2024

Contents Open

Tian Tu, Benno Zehnder, Bing Qu, S. Cabrera Urbán, Mette Vesterhus , et al. · 2024

Impact of Hepatitis C Virus Direct Acting Antivirals on Hepatocellular Carcinoma Evolution Open

Stanislas Pol, Laurent Lam, Charlotte Mouliade, Fabrice Carrat · 2024

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline Open

Ahmed A. Awan, Marina Berenguer, Annette Bruchfeld, Fabrizio Fabrizi, David S. Goldberg , et al. · 2023

The 2022 updated guideline includes 43 graded recommendations and 20 ungraded recommendations, 7 of which are new or modified on the basis of the most recent evidence and consensus among the WG members. The updated guidelines recommend exp…

COVID-19 and excess mortality of patients with liver cancer in France, January 2020–September 2022 Open

Stylianos Tzedakis, Ortal Yzhaky Shapira, Michaël Schwarzinger, Sandrine Katsahian, Andréa Lazzati , et al. · 2023

International audience

Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis Open

Thierry Poynard, Olivier Deckmyn, Valentina Peta, Valérie Paradis, Jean‐François Gautier , et al. · 2023

Summary Background No prospective diagnostic studies have directly compared widespread non‐invasive liver tests in patients with type 2 diabetes (T2D) using the intention‐to‐diagnose method for each of the three main histological features …

Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort) Open

Patrizia Carrieri, Marc Bourlière, Vincent Di Beo, Clovis Lusivika‐Nzinga, Clémence Ramier , et al. · 2023

Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors Open

Lucia Parlati, Mehdi Sakka, A. Retbi, Samir Bouam, L. Hassani , et al. · 2023

There is concern about liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). We investigated the burden of grade 3/4 liver injury after treatment with ICIs in a multicentric cohort of patients with cancer. O…

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later? Open

Raffaele Brustia, Mohamed Bouattour, Manon Allaire, Marie Lequoy, Clémence Hollande , et al. · 2023

Disruption of routine healthcare services because of the pandemic translated to reduced 1 year overall and disease-free survival among patients affected by HCC, in the metropolitan area of Paris, France.

Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study Open

Laurent Lam, Stanislas Pol, Ariel Cohen, Fabrice Carrat · 2023

COVID-19 and excess mortality of patients with liver cancer in France, January 2020-September 2022 Open

Stylianos Tzedakis, Ortal Yzhaky Shapira, Michaël Schwarzinger, Sandrine Katsahian, Andréa Lazzati , et al. · 2023

Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study Open

Lucia Parlati, Kennie Marcin, Benoît Terris, Anaïs Vallet‐Pichard, Marion Corouge , et al. · 2023

Background and aims: the side effects of immune checkpoint inhibitors (ICI) pose a problem for the clinical management of cancer patients. There is a lack of knowledge of the value of liver biopsy in patients with ICI-related drug-induced …

Contents Open

Travis Y. Tu, Benno Zehnder, Bin Qu, S. Cabrera Urbán, Mette Vesterhus , et al. · 2023

Unknown Circovirus in Immunosuppressed Patient with Hepatitis, France, 2022 Open

Christophe Rodriguez, Laure Boizeau, Alexandre Soulier, Mélissa N’Debi, Vanessa Démontant , et al. · 2023

Hepatitis of undetermined origin can be caused by a wide variety of pathogens, sometimes emerging pathogens. We report the discovery, by means of routine shotgun metagenomics, of a new virus belonging to the family Circoviridae, genus Circ…

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold Open

Laurent Castéra, Cédric Laouénan, Anaïs Vallet‐Pichard, Tiphaine Vidal-Trécan, Pauline Manchon , et al. · 2023

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter prospective st…

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold Open

Laurent Castéra, Cédric Laouenan, Anaïs Vallet‐Pichard, Tiphaine Vidal-Trécan, Pauline Manchon , et al. · 2023

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis (AF) remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter, prospective study assessed …

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold Open

Laurent Castéra, Cédric Laouénan, Anaïs Vallet‐Pichard, Tiphaine Vidal-Trécan, Pauline Manchon , et al. · 2023

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter prospective st…

Suppl_Figure1 from HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management Open